公开(公告)号：US20240342097A1

公开(公告)日：2024-10-17

申请号：US18755717

申请日：2024-06-27

申请人： DPL PHARMA S.P.A.

发明人： Massimo Pedrani ,  Chiara Conti ,  Salvatore Agostino Giammillari ,  Giuseppe Maccari

IPC分类号： A61K9/28

CPC分类号： A61K9/2886 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/288

摘要： The present invention relates to solid oral controlled-release pharmaceutical compositions comprising a core consisting of a complex monolithic matrix comprising at least one low/medium viscosity hydroxypropyl methylcellulose, at least one medium/high viscosity hydroxypropyl methylcellulose, one or more methacrylic polymers or copolymers and/or cellulose acetate phthalate and/or hydroxypropyl methylcellulose acetate succinate or shellac, and an outer coating of said core consisting of a layer comprising ethylcellulose, or of a gastroresistant layer or of a layer comprising ethylcellulose coated in turn with gastroresistant polymers.

公开(公告)号：US20240285539A1

公开(公告)日：2024-08-29

申请号：US18567236

申请日：2022-06-03

申请人： R.P. Scherer Technologies, LLC

发明人： Todd Anthony STUTZMAN ,  Allissa Robin KERNER ,  Joseph Michael SCHNITZ ,  Daniela CIOLOBOC

IPC分类号： A61K9/28 ,  A61K31/4545 ,  A61K33/24

CPC分类号： A61K9/2886 ,  A61K9/2846 ,  A61K9/288 ,  A61K31/4545 ,  A61K33/24

摘要： Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions comprising wax coated tablets. Specifically, a wax coating can be applied to a pharmaceutical tablet prior to the film coating process.

公开(公告)号：US12053482B2

公开(公告)日：2024-08-06

申请号：US18138473

申请日：2023-04-24

申请人： Celgene Corporation

发明人： Jeffrey B. Etter ,  Mei Lai ,  Jay Thomas Backstrom

IPC分类号： A61K31/706 ,  A61K9/20 ,  A61K9/28 ,  A61K31/7068 ,  A61K47/10

CPC分类号： A61K31/706 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/2886 ,  A61K31/7068 ,  A61K47/10

摘要： The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.

公开(公告)号：US11986554B2

公开(公告)日：2024-05-21

申请号：US17389612

申请日：2021-07-30

申请人： DEXCEL PHARMA TECHNOLOGIES LTD.

发明人： Sheera Moses-Heller

IPC分类号： A61K31/4439 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K9/28 ,  A61K9/50 ,  A61K31/4184

CPC分类号： A61K9/0056 ,  A61K9/1623 ,  A61K9/1676 ,  A61K9/2072 ,  A61K9/2081 ,  A61K9/2086 ,  A61K9/28 ,  A61K9/2886 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5078 ,  A61K31/4184 ,  A61K31/4439

摘要： An orally disintegrating dosage form of a proton pump inhibitor, methods for its production and use thereof are provided. The dosage form includes a plurality of pellets containing a proton pump inhibitor admixed with a disintegrant to afford rapid disintegration in the oral cavity after administration.

公开(公告)号：US20240050464A1

公开(公告)日：2024-02-15

申请号：US18372162

申请日：2023-09-25

申请人： Viscera Labs, Inc.

发明人： Stephen TAGLIENTI ,  Steven L. PETRUCCELLI

IPC分类号： A61K31/785 ,  A61K9/28 ,  A61K9/20 ,  A61K45/06

CPC分类号： A61K31/785 ,  A61K9/2886 ,  A61K9/2866 ,  A61K9/2054 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/282 ,  A61K45/06

摘要： In exemplary embodiments, the disclosure provides a Colesevelam Colon Specific Drug Delivery System for use in treatment of, for example pruritus, a disorder related to elevated serum cholesterol concentration, or reducing elevated low-density lipoprotein cholesterol (LDL) concentration in a patient.

公开(公告)号：US20230398173A1

公开(公告)日：2023-12-14

申请号：US18456852

申请日：2023-08-28

申请人： Ironwood Pharmaceuticals, Inc. ,  Forest Laboratories Holdings Limited

发明人： Angelika Fretzen ,  Mark G. Currie ,  Ahmad Hashash ,  Mahendra Dedhiya ,  Yun Mo ,  Anil Chhettry ,  Matthew Miller ,  Ritesh Sanghvi ,  Mohammad Mafruhul Bari ,  Andreas Grill

IPC分类号： A61K38/10 ,  A61K9/16 ,  A61K9/20 ,  A61K9/28 ,  A61K9/48 ,  A61K9/50

CPC分类号： A61K38/10 ,  A61K9/1611 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2846 ,  A61K9/4891 ,  A61K9/1676 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/284 ,  A61K9/2886 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866 ,  A61K9/4808 ,  A61K9/1652 ,  A61K9/4825

摘要： The present invention relates to delayed release pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.

公开(公告)号：US20230372241A1

公开(公告)日：2023-11-23

申请号：US18366945

申请日：2023-08-08

申请人： FP NUTRACEUTICALS, LLC

发明人： Timothy McCoy Marshall

IPC分类号： A61K9/00 ,  A61K9/70 ,  A61K9/28 ,  A61K9/16

CPC分类号： A61K9/006 ,  A61K9/7007 ,  A61K9/2886 ,  A61K9/2826 ,  A61K9/1652

摘要： The oral cavity is an ideal-site for small molecule, nutrient and/or nutraceutical delivery to the systemic circulation due to the highly-vascularized, oral mucosa, near-neutral pH conditions, and avoidance of gastric and first-pass degradation. Accordingly, novel, saccharide-based, food-form, portable, individually wrapped, oral delivery systems that attach to these four, highly absorptive surfaces (e.g. gingival, buccal, soft palatal, sublingual) for a longer contact-duration than current orally available formulas resulting in greater, small molecule bioavailability, and a more rapid, therapeutic effect are preferred and described.

公开(公告)号：US20230293445A1

公开(公告)日：2023-09-21

申请号：US18323474

申请日：2023-05-25

申请人： CLEXIO BIOSCIENCES LTD.

发明人： Dinesh K. Haswani ,  Derek V. Moe ,  Victoria A. O'Neill ,  Randal A. Seburg ,  Manuel A. Vega Zepeda

IPC分类号： A61K9/50 ,  A61K9/28 ,  A61K45/06 ,  A61K31/4458 ,  A61K47/58 ,  A61K31/00 ,  A61K9/20 ,  A61K31/136 ,  A61K31/137 ,  A61K31/165 ,  A61K31/167 ,  A61K31/437 ,  A61K31/485 ,  A61K31/515 ,  A61K31/5513 ,  A61K31/554 ,  A61K47/61 ,  A61K47/54 ,  A61K47/59 ,  A61K9/00 ,  A61K31/135

CPC分类号： A61K9/5078 ,  A61K9/2886 ,  A61K9/5073 ,  A61K45/06 ,  A61K31/4458 ,  A61K47/58 ,  A61K31/00 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K31/136 ,  A61K31/137 ,  A61K31/165 ,  A61K31/167 ,  A61K31/437 ,  A61K31/485 ,  A61K31/515 ,  A61K31/5513 ,  A61K31/554 ,  A61K47/61 ,  A61K47/543 ,  A61K47/59 ,  A61K9/0053 ,  A61K9/204 ,  A61K9/2081 ,  A61K31/135

摘要： Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.

公开(公告)号：US20230277466A1

公开(公告)日：2023-09-07

申请号：US18185584

申请日：2023-03-17

申请人： Theriva Biologics, Inc.

发明人： Andrew BRISTOL ,  Ray STAPLETON ,  Michael KALEKO ,  Christian FURLAN FREGUIA ,  Steven HUBERT ,  Cristina FREIRE ,  James GUBBINS

IPC分类号： A61K9/28 ,  A61K9/20 ,  A61K38/46 ,  A61K9/19 ,  C12N9/16 ,  C12N15/63 ,  C12N15/52

CPC分类号： A61K9/2846 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2893 ,  A61K9/2095 ,  A61K38/465 ,  C12Y301/03001 ,  A61K9/2013 ,  A61K9/2866 ,  A61K9/19 ,  A61K9/2009 ,  C12N9/16 ,  A61K9/2018 ,  A61K9/2886 ,  C12N15/63 ,  C12N15/52

摘要： The present invention provides for a formulation comprising an active alkaline phosphatase (AP)-based agent and an enteric agent, wherein the formulation is suitable for releasing a substantial amount of the active AP-based agent in the intestines.

公开(公告)号：US20230255996A1

公开(公告)日：2023-08-17

申请号：US18138473

申请日：2023-04-24

申请人： Celgene Corporation

发明人： Jeffrey B. Etter ,  Mei Lai ,  Jay Thomas Backstrom

IPC分类号： A61K31/706 ,  A61K47/10 ,  A61K9/20 ,  A61K31/7068 ,  A61K9/28

CPC分类号： A61K31/706 ,  A61K47/10 ,  A61K9/2018 ,  A61K31/7068 ,  A61K9/2013 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/2886

摘要： The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.